Yali Chang1,2, Xiangling Xing1,3,4, Yang Jiang1,3,4, Xiaoyun Shi1,3,4, Yaqi Xu1,3,4, Ai Li1,3,4, Xiaoli Feng5, Yuan Zhang6, Dexiao Kong7,3,4, Chengyun Zheng1,3,4. 1. Department of Hematology, The Second Hospital of Shandong University. 2. Department of Hematology, Jinan Central Hospital affiliated to Shandong University. 3. Institute of Biotherapy for Hematological Malignancies, Shandong University. 4. Shandong University-Karolinska Institute Collaborative Laboratory for Stem Cell Research, Shandong University. 5. Clinical Laboratory, The Second Hospital of Shandong University. 6. Center of Evidence-based Medicine, The Second Hospital of Shandong University, Jinan, Shandong Province, China. 7. Department of Hematology, The Second Hospital of Shandong University kdx2002@126.com.
Abstract
BACKGROUND: Multiple myeloma (MM) is one of the most common types of hematological malignancies, but its pathogenesis is poorly understood. Interleukin-9 (IL-9) is a growth factor, mainly produced by helper T cells. A series of observations suggested that IL-9 might act as a factor promoting oncogenesis. This study was aimed at detecting the serum concentrations of IL-9 in patients with MM, and to investigate its potential clinical significance. METHODS: The serum IL-9 levels in 34 patients with MM and 15 normal controls were quantified by using the Enzyme Linked Immunosorbent Assay (ELISA). RESULTS: Our results showed that the serum IL-9 concentration in MM patients was significantly higher than that in the controls (p<0.0001). Interestingly, the IL-9 level in serum was found to be negatively associated with the hemoglobin concentration among the newly diagnosed MM patients (p=0.0108, r=-0.5850). Moreover, MM patients with renal dysfunction showed a significant increase in serum IL-9 concentration over those with normal renal function (p=0.0395). CONCLUSION: These findings may imply a novel role of IL-9 in anemia and/or renal dysfunction development in MM.
BACKGROUND:Multiple myeloma (MM) is one of the most common types of hematological malignancies, but its pathogenesis is poorly understood. Interleukin-9 (IL-9) is a growth factor, mainly produced by helper T cells. A series of observations suggested that IL-9 might act as a factor promoting oncogenesis. This study was aimed at detecting the serum concentrations of IL-9 in patients with MM, and to investigate its potential clinical significance. METHODS: The serum IL-9 levels in 34 patients with MM and 15 normal controls were quantified by using the Enzyme Linked Immunosorbent Assay (ELISA). RESULTS: Our results showed that the serum IL-9 concentration in MMpatients was significantly higher than that in the controls (p<0.0001). Interestingly, the IL-9 level in serum was found to be negatively associated with the hemoglobin concentration among the newly diagnosed MMpatients (p=0.0108, r=-0.5850). Moreover, MMpatients with renal dysfunction showed a significant increase in serum IL-9 concentration over those with normal renal function (p=0.0395). CONCLUSION: These findings may imply a novel role of IL-9 in anemia and/or renal dysfunction development in MM.